CATALOGO DEI PRODOTTI DELLA RICERCA

MAURELLI, MARTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.623
EU - Europa 1.398
AS - Asia 1.373
SA - Sud America 195
AF - Africa 46
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.648
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.580
SG - Singapore 540
CN - Cina 282
IT - Italia 236
HK - Hong Kong 207
DE - Germania 202
BR - Brasile 172
RU - Federazione Russa 165
GB - Regno Unito 163
IE - Irlanda 150
FR - Francia 135
SE - Svezia 112
FI - Finlandia 99
KR - Corea 69
IN - India 63
JP - Giappone 59
ID - Indonesia 38
NL - Olanda 32
CA - Canada 27
ES - Italia 26
SA - Arabia Saudita 25
TG - Togo 25
VN - Vietnam 20
AT - Austria 16
UA - Ucraina 15
TR - Turchia 14
BE - Belgio 12
MX - Messico 12
AR - Argentina 8
AU - Australia 8
EG - Egitto 8
IR - Iran 8
HU - Ungheria 7
IL - Israele 6
BD - Bangladesh 5
IQ - Iraq 5
KE - Kenya 5
TW - Taiwan 5
CL - Cile 4
MY - Malesia 4
NZ - Nuova Zelanda 4
PL - Polonia 4
ZA - Sudafrica 4
CH - Svizzera 3
CZ - Repubblica Ceca 3
GR - Grecia 3
LK - Sri Lanka 3
PK - Pakistan 3
BG - Bulgaria 2
BH - Bahrain 2
BN - Brunei Darussalam 2
EC - Ecuador 2
GE - Georgia 2
GT - Guatemala 2
JO - Giordania 2
PE - Perù 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
UY - Uruguay 2
VE - Venezuela 2
AM - Armenia 1
AZ - Azerbaigian 1
BJ - Benin 1
BW - Botswana 1
CO - Colombia 1
CY - Cipro 1
DK - Danimarca 1
GF - Guiana Francese 1
HN - Honduras 1
HR - Croazia 1
LB - Libano 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
MN - Mongolia 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
PY - Paraguay 1
SI - Slovenia 1
TN - Tunisia 1
UZ - Uzbekistan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.648
Salva come PNG Salva come JPEG
Città #
Dallas 458
Chandler 244
Singapore 238
Hong Kong 204
Dublin 138
Ashburn 122
Munich 110
Southend 87
Beijing 77
Helsinki 68
Jacksonville 42
New York 41
Verona 37
Lawrence 34
Princeton 34
Wilmington 28
Jakarta 27
Lomé 25
Milan 24
Amsterdam 21
London 21
Los Angeles 21
Riyadh 20
Sindelfingen 20
Woodbridge 20
Paris 19
Washington 18
Lappeenranta 16
Monza 16
Jinan 15
Santa Clara 15
Seattle 15
São Paulo 15
Madrid 14
Nuremberg 14
Bologna 12
Mumbai 12
Rome 12
Bethnal Green 11
Chennai 11
Frankfurt am Main 11
Ghaziabad 11
Manchester 11
Tokyo 11
Ann Arbor 10
Boston 10
Houston 10
Liverpool 10
Nanjing 10
Chicago 9
The Dalles 9
Brasília 8
Dongguan 8
Guangzhou 8
Ho Chi Minh City 8
Redwood City 8
Chieri 7
Fairfield 7
Giza 7
Marseille 7
Wakabadai 7
Brussels 6
Budapest 6
Gurugram 6
Igusa 6
Jyväskylä 6
Minamimotomachi 6
Montreal 6
Moscow 6
Shanghai 6
Vancouver 6
Vienna 6
Ankara 5
Atlanta 5
Bari 5
Brindisi 5
Coquitlam 5
Hanover 5
Konya 5
Redmond 5
San Jose 5
Shenyang 5
Toronto 5
Belo Horizonte 4
Brooklyn 4
Changsha 4
Columbus 4
Curitiba 4
Delhi 4
Hangzhou 4
Hanoi 4
Hebei 4
Jiaxing 4
Kent 4
Liège 4
Luoyang 4
Miami 4
Nairobi 4
Nanchang 4
Padua 4
Totale 2.752
Salva come PNG Salva come JPEG
Nome #
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS) 253
A systematic review of treatments for pityriasis lichenoides 240
Long-term therapeutic response to dupilumab in patients affected by prurigo nodularis: A real-world retrospective study 174
Safety and Effectiveness of Dupilumab in Atopic Dermatitis Patients with Hematologic Comorbidities: A Multicenter, Retrospective Study 142
Upadacitinib improves symptoms of concomitant allergic rhinitis or allergic asthma in patients with severe atopic dermatitis: A 16-week multicentre retrospective study 120
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series 106
BRAF V600E expression in juvenile xanthogranuloma occurring after Langerhans cell histiocytosis. 98
Gender perspective in the management of psoriasis 97
Incidence and ten-year follow-up of primary cutaneous lymphomas: a single-centre cohort study 96
Clinical features and treatments of transient acantholytic dermatosis (Grover’s disease): a systematic review 91
Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid 91
Neutrophilic figurate erythema: report of a new case in an adult and comparison between adult and paediatric cases 89
Acquired perforating dermatoses show increased levels of cutaneous advanced glycation end-products 87
A case of genital primary syphilis with superimposed impetigo 83
Alopecic and aseptic nodules of the scalp: A new case with a systematic review of the literature 83
Amicrobial Pustulosis of the Folds: Report of Three New Cases 81
null 80
Primary Cutaneous CD4+ Small/Medium Pleomorphic T-Cell Lymphoproliferative Disorder: A Case Series 77
Psoriasin (S100A7) is increased in serum of patients with moderate to severe psoriasis 77
Persistent localized hypertrichosis in a Caucasian child at sites of DTPa and chickenpox vaccination 73
Annually Recurring Erythema Annulare Centrifugum: A New Case Series with Review of the Literature 72
Adrenergic urticaria successfully treated with omalizumab 72
A man with a widespread bullous eruption 70
Idiopathic lichenoid and granulomatous dermatitis 70
Interferon-beta injection site reactions in patients with multiple sclerosis. 69
Annular Erythema: New and Revisited Variants 69
Biological agents targeting interleukin-13 for atopic dermatitis 69
Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo 68
Clinical profile and co-infections of urethritis in males 66
Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease 66
Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines 65
Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis 64
Advanced Glycation End Products and Psoriasis 64
Milia-like calcinosis cutis in Down syndrome: a new case with a review of the literature 64
Severe cutaneous aluminum reaction to quadrivalent human papillomavirus vaccine treated with cyclosporin 60
Uncommon Non‑Infectious Annular Dermatoses 59
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis 58
Eosinophilic annular erythema successfully treated with cyclosporine 58
Price variability of TNF-α inhibitor biosimilars among European countries 58
Visual Vignette 55
IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review 55
Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients 54
Palisaded neutrophilic granulomatous dermatitis and its associations with autoimmune diseases 53
Advanced Glycation End Products are Increased in the Skin and Blood of Patients with Severe Psoriasis 51
Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis 51
Lichen planopilaris coexisting with plaque psoriasis effectively treated with brodalumab 51
Long‑Term Effectiveness and Safety of Ixekizumab for the Treatment of moderate‑to‑Severe Plaque Psoriasis: A Five‑Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis) 48
The emerging role of the neuroimmune cytokine interleukin-31 in chronic inflammatory skin diseases 48
Targeting IL-4 for the Treatment of Atopic Dermatitis 47
Is risankizumab as needed administration a good option for patients with plaque psoriasis? 46
Atopic Dermatitis in the Elderly Population 45
Variations of symptoms of atopic dermatitis and psoriasis in relation to menstrual cycle 43
Pruritus as a Distinctive Feature of Type 2 Inflammation 43
Tailored biological treatment for patients with moderate-to-severe psoriasis 40
Managing the Patient with Psoriasis and Metabolic Comorbidities 39
Long-term effectiveness and tolerability of apremilast in patients with moderate-to- severe plaque psoriasis: A 5-year multicentre retrospective study—IL PSO (Italian landscape psoriasis) 38
Lymphoplasmacytic plaque effectively treated with imiquimod 38
Reduction of cutaneous advanced glycation end products levels after effective psoriasis treatment 37
Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study 36
The Combination of Dupilumab with Other Monoclonal Antibodies 35
Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience 34
Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patients 33
Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis 32
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS) 30
Overview of Atopic Dermatitis in Different Ethnic Groups 28
Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis 28
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study 26
Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes 25
Safety and Efectiveness of Upadacitinib in Patients with Moderate‐to‐Severe Atopic Dermatitis Who Smoke: a 2‐Year Real‐Life Multicenter Study 20
Successful response of upadacitinib in different clinical phenotypes of atopic dermatitis 19
Efcacy and safety of JAK inhibitors in patients aged >60 years with moderate‐to‐severe atopic dermatitis: a 52‐week multicenter, real‐life study—IL AD (Italian Landscape Atopic Dermatitis) 17
Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260‐Week Real‐World Multicenter Retrospective Study Exploring the Role of Concomitant PsA–IL PSO (Italian Landscape Psoriasis) 16
Totale 4.740
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.088
article - articoli 20.725
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 363
Totale 42.176
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021101 0 0 3 21 19 16 10 1 6 2 13 10
2021/2022228 13 26 0 18 31 6 6 23 4 14 30 57
2022/2023738 38 68 63 134 58 187 16 34 90 13 25 12
2023/2024647 16 30 56 51 52 126 115 42 8 39 71 41
2024/20251.894 119 63 98 291 80 115 168 111 244 136 143 326
2025/2026877 293 169 415 0 0 0 0 0 0 0 0 0
Totale 4.740